drugset
drugset / Trial / NCT06734871

A Clinical Study Exploring CT1190B in the Treatment of Patients with Relapsed/refractory B-cell Non-Hodgkin Lymphoma

NCT06734871 ↗

Phase 1 Recruiting 24 enrolled Aibin Liang，MD，Ph.D.
NaSingle-groupOpen-labelTreatment

Summary

A Clinical Study to Investigate the Safety, Efficacy, and Cellular Metabolism of CT1190B CAR-T Cell therapy, in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma.

Timeline

Start
2024-12-30
Primary completion
2025-10-13
Completion
2026-07-13

Drugs

EvaluationDrugModalityDoseRoute
Subject CT1190B Cell therapy — —

Indications

B-cell non-Hodgkin lymphoma